Solstice Advanced Materials Inc. (SOLS) stock intrinsic value fair value estimate & owner earnings analysis

Solstice Advanced Materials is the former Honeywell specialty-materials business, spun off as an independent company at the end of October 2025. It has two segments. Refrigerants & Applied Solutions (2025 sales $2,789M) makes the Solstice line of low global-warming refrigerants, blowing agents and propellants (led by R-1234yf, the standard refrigerant in new cars, and R-1234ze/R-454B blends for heating and cooling), Aclar healthcare packaging films, and uranium hexafluoride conversion at the Metropolis, Illinois plant, the only U.S. conversion facility, sold through the ConverDyn joint venture with General Atomics. Electronic & Specialty Materials (2025 sales $1,097M) makes sputtering targets and other semiconductor materials, Spectra ultra-high-molecular-weight fiber and Fluka research chemicals. Total sales were $3,649M in 2023, $3,770M in 2024 and $3,886M in 2025; about 57% are booked in the United States. The main driver is regulation. The U.S. AIM Act and the European F-gas rules are cutting the allowed supply of older high-warming refrigerants on a fixed legal schedule, which pushes equipment makers and car makers toward the low-warming molecules Solstice patented and builds at scale. Composition patents on R-1234yf run into the 2030s and patents on blends and manufacturing methods at least into the mid-2030s; some application patents have already expired. That end date matters for the long-term value and is built into every case. Earning power. We measure the cash an owner could take out each year: operating cash flow, minus the swing in working capital, minus stock compensation, minus the capital spending needed to keep the plants as they are, and minus the share that belongs to General Atomics as the outside partner in ConverDyn (consolidated in full). On that basis the business earned about $481M in 2023 ($3.03 per share), $500M in 2024 ($3.15) and $172M in 2025 ($1.08). The 2025 figure is distorted by one-time costs of separating from Honeywell: $117M of transaction costs and roughly 32 percentage points of extra tax rate from separation-related taxes (a 56% effective rate versus 24% in the prior two years). Adding those back puts 2025 near $490-500M, in line with the earlier years. The 2023 and 2024 figures come from carve-out statements that relied on Honeywell for many corporate functions; running as a stand-alone company costs more (corporate costs rose $23M in 2025 alone) and refrigerant margins fell in 2025 as the product mix shifted during the transition (segment profit down $77M). The first half of 2026 shows net income attributable to shareholders of $204M versus $231M a year earlier, and capital spending is running at the $400-425M the company has planned, most of it for new electronic-materials and fiber capacity. We therefore anchor on about $440M a year of cash before interest payments, below the carve-out years, rather than the $500M those years suggest. The single depressed 2025 figure was not used as the anchor and neither was the first half of 2026 alone. Amortization of acquired intangibles is small (about $4M a year), so very little value comes from adding back non-cash charges. The asset that runs out here is the refrigerant patent estate, and its expiry is built into the later years of each case. Debt. At June 30, 2026 the company owed about $1,972M ($1.0B of 5.625% notes due 2033 and a $1.0B term loan due 2032 at SOFR plus 1.75%) plus $109M of finance leases, against $750M of cash. Treating about $200M of cash as needed to run the business leaves net debt of about $1,531M, or roughly $9.60 per share. The fixed notes cost close to a long-bond rate and the term loan floats, so no adjustment for the cost of debt was needed. Nothing matures before 2032, and interest of roughly $105-110M a year is covered about four times by cash flow before interest, so every case carries its own debt. Base case: about $440M of cash before interest in 2027, growing about 3% a year for three years as the legally scheduled U.S. and European refrigerant phase-down steps move more volume to the newer molecules, then slower growth near 1% as the transition matures. After the mid-2030s, when the R-1234yf patents lapse, we assume earnings stop growing at about $430M a year and hold there, supported by the know-how, trade secrets and plant base the company describes, its uranium conversion position and its electronics business. New capacity for electronics and Spectra fiber is not credited because its returns are not yet shown in results. The business is worth about $7.5B; less $1.5B of net debt leaves about $6.0B, or $37.50 per share. Bear case: a recession of the 2008-2009 kind, when U.S. car sales fell about a third and heating and cooling equipment shipments dropped sharply, hits in 2027-2028: cash before interest falls from $440M to about $290-300M for two years, then recovers to about $400M. Then, as the R-1234yf composition patents expire in the 2030s, competing producers (including lower-cost Asian makers) pull refrigerant pricing down, and cash before interest settles near $300M a year for good. Even in this case the debt remains serviceable, with interest covered nearly three times at the trough. The business is worth about $5.5B; less net debt of $1.5B leaves about $3.9B, or $24.68 per share. Bull case: the refrigerant transition proceeds on its legal schedule with pricing holding as it has over the past three years, the stand-alone cost base settles, and cash before interest starts near $470M and grows about 4% a year for five years, then more slowly, reaching about $620M by the early 2030s, with the know-how keeping margins even after the patents expire. The business is worth about $9.8B; less net debt leaves about $8.2B, or $51.71 per share. What could make this wrong: the carve-out history may overstate what the stand-alone company can earn; we have only one full year of separate results and part of that was distorted. The amount of refrigerant pricing that survives patent expiry is the largest uncertainty. The Metropolis uranium plant carries decommissioning obligations and depends on its license and on ConverDyn's contracts. A large share of the plant spending now underway is for new products whose payoff has not yet been proven. Margin-of-safety price. We are moderately sure of the earnings level: three years of results fall in a narrow $480-510M band before one-time items, but they come from carve-out accounts, and the 2025-2026 stand-alone results are lower. The worst plausible outcome is a deep recession landing just as refrigerant patents expire and new competitors arrive. With nothing maturing until 2032, interest covered roughly four times, and a hard asset base of 20 manufacturing sites and the only U.S. uranium conversion plant, the business would survive that without needing new equity. If we are wrong about the stand-alone earnings level (say $400M rather than $440M) and about how much pricing survives the patents, the shares would be worth around the low to mid $20s. The price assumes a three-to-five-year holding period; the company pays only a small dividend (about $24M in the first half of 2026, roughly $0.30 per share a year), so nearly all of the return has to come from the business's value being recognized. At $22 a share the price sits below what the shares appear to be worth even in a recession-plus-patent-loss story, and if the base case plays out over four years the value would compound to roughly $45-47, which implies more than a 20% annual return from $22. The margin-of-safety price is $22. Our previous estimate was built on a different basis and is not comparable to these figures.